
SXTP Stock Forecast & Price Target
SXTP Analyst Ratings
Bulls say
60 Degrees is well positioned for growth with the potential success of its current pipeline in infectious diseases. The company's ARAKODA commercial buildout and partnerships with GoodRx and Runway Health demonstrate efforts to improve affordability and broaden patient access. However, risks associated with regulatory approval and potential dilution from future capital raises may impact the company's stock performance. The recent 1:4 reverse stock split and additional dilution from recent ATM sales have led to an adjusted price target of $4.20, representing 130% upside from the current share price. Fundamentals of the company, such as cash on hand and potential future financing, should also be monitored closely as they may affect the company's financial health.
Bears say
60 Degrees is facing challenges with their ARAKODA revenue trajectory, potential limitations in funding future clinical development programs, and a low cash balance of $3.3 million. Additionally, their Q1 FY26 product revenue has declined due to higher returns and lower sell-through, with US pharmacy/dispensary unit sales decreasing by 19%. While the company shows potential in filling an unmet need in infectious diseases, the current financial constraints and lack of visibility on ongoing development plans make it difficult to maintain a positive outlook. Their clinical progress on tafenoquine for Babesiosis shows promise, but funding limitations and uncertainties surrounding their financials warrant a rating downgrade to Neutral at this time.
This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
SXTP Analyst Forecast & Price Prediction
Start investing in SXTP
Order type
Buy in
Order amount
Est. shares
0 shares